Article Type: Review Article

Subheading: Obstetrics

**Accuracy of on-site tests to detect anemia during prenatal care**

Soha Sobhy 1·*, Ewelina Rogozinska 1,2, Khalid S Khan 1,2

1 Women’s Health Research Unit, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

2 Multidisciplinary Evidence Synthesis Hub, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

* Correspondence

Soha Sobhy, Women’s Health Research Unit, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Email: soha.sobhy@qmul.ac.uk

**Keywords:** Anemia; On-site tests; Point-of-care tests; Pregnancy; Prenatal care; Screening

**Synopsis:** The copper sulfate, Sahli method, and HemoCue tests were found to be accurate tools for the detection of anemia during pregnancy.
Abstract

Background: Anemia is a substantial contributor to poor pregnancy outcomes in low- and middle-income countries. Access to laboratory facilities is limited; therefore, on-site testing warrants attention.

Objectives: To determine the accuracy of on-site tests to detect anemia in pregnancy.

Search strategy: MEDLINE, Embase, Scopus, CINAHL, and Web of Science were searched from inception until March 2016, with no language restrictions, using the terms “pregnancy,” “anemia,” and “hemoglobin.”

Selection criteria: Studies that evaluated the diagnostic accuracy of on-site hemoglobin tests versus laboratory-based reference tests during pregnancy were included.

Data collection and analysis: Study characteristics and true positive, true negative, false positive, and false negative rates were extracted. Sensitivity, specificity, likelihood ratios, and post-test probabilities were calculated. Anemia was defined as a hemoglobin level of less than 110 g/L.

Main results: Ten studies (4239 participants) were assessed. Copper sulfate provided 97% sensitivity (95% confidence interval [CI] 88%–100%) and 71% specificity (95% CI 55%–85%); the Sahli method provided 86% sensitivity (95% CI 75%–94%) and 83% specificity (95% CI 68%–93%); and HemoCue provided 85% sensitivity (95% CI 79%–90%) and 80% specificity (95% CI 76%–83%).

Conclusions: Some on-site tests are accurate and should be made widely available to improve detection of anemia in pregnancy.
1 INTRODUCTION

Maternal anemia—defined as a low blood hemoglobin concentration—remains a serious global health problem. This condition is detected among 42% of all women during pregnancy; Africa and Southeast Asia are the most affected geographic regions [1,2]. An estimated 56 million pregnant women have anemia; furthermore, the rate of this condition has declined by only 5% since 1995 [1].

Anemia is the most frequent indirect cause of adverse maternal outcomes and mortality, contributing to up to 50% of both [3]. The risks of macerated late fetal death, fresh late fetal death, and early neonatal death are consistently increased among mothers with severe anemia [4]. A link has also been found between anemia and low birth weight, small for gestational age, and preterm birth [2,5]. Furthermore, women with anemia are less likely to overcome the adverse effects of excessive blood loss and are more susceptible to infection, fatigue, and depression than are women without this disorder [6].

Testing for anemia is done infrequently and with low accuracy in low-income and middle-income countries (LIMICs), especially in rural locations. In this setting, anemia can go undetected because diagnosis is often based on symptoms and physical examination rather than on objective testing [7]. Laboratory measurement of cyanmethemoglobin by spectrometry is the gold standard, but use of this test is hampered by high cost and low availability [8]. Consequently, simple, safe, accurate, and low-cost hemoglobin assessment tools were introduced to address this issue [9]. On-site testing to detect anemia is a potential option to increase accessibility. Methods currently in use include HemoCue (HemoCue, Ängelholm, Sweden), WHO
hemoglobin color scale (HCS), and copper sulfate; however, their diagnostic accuracy is not well characterized.

Systematic reviews have been published on the accuracy of HCS, HemoCue, and non-invasive methods but they did not include studies exclusively conducted in a prenatal care setting [10,11]. The threshold used to diagnose anemia in pregnancy differs from that of a nonpregnant population [12]. Previous reviews have included a mixed population, which is a key deficiency because disease spectrum variation has an impact on accuracy [13,14]. Reviews have also used HemoCue as a reference test [11] because it is more widely available than the gold-standard laboratory test in low-income countries. Nonetheless, measurement of hemoglobin concentration by HemoCue provides lower precision than that of automated analyzers, and its precision also varies by sample type (i.e. whether the sample is taken from a capillary or vein) [15–17].

Therefore, the aim of the current systematic review was to determine the accuracy of on-site tests to detect anemia among pregnant women in LIMICs.

2 MATERIALS AND METHODS
A systematic review of on-site testing for maternal anemia was conducted in line with current recommendations. The protocol was registered with the PROSPERO international prospective register of systematic reviews (CRD42015029172), and methods of data reporting adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines [18].
2.1 Literature search

The MEDLINE, Embase, Scopus, CINAHL, and Web of Science databases were searched for relevant studies from inception until March 21, 2016. No language restrictions were imposed on the literature search. Medical subject headings, text words, and word variants for "pregnancy" were combined with the terms "an(a)emia" and "h(a)emoglobin," with exclusion ("NOT") of words relating to the fetus such as "cord," “neonatal,” and “placenta” (Appendix S1). The reference lists of the included studies and relevant reviews were searched for additional eligible studies.

2.2 Study selection

A two-stage process was used to select studies for inclusion in the present systematic review. First, the titles and abstracts of all citations were screened for potential relevance. Second, SS and ER independently examined the full text of the retrieved papers using prespecified inclusion criteria; discrepancies were resolved by discussion with KSK. The inclusion criteria were recruitment of pregnant women attending prenatal care, comparison of any on-site test for hemoglobin concentration with a laboratory-based reference test, and provision of diagnostic accuracy data. Case–control studies, prevalence studies, and studies that enrolled non-pregnant populations were excluded.

2.3 Data extraction and quality assessment

Data extraction and assessment of study quality were performed by SS and ER, with discrepancies resolved following input from KSK. Data were extracted using a standardised pre-piloted form. Information on the type of test, setting, sample (venous or capillary blood), and the type of practitioner who conducted the tests was
included. Data were extracted for different thresholds of hemoglobin concentration as per WHO standards [12]. Anemia in pregnancy was defined as a hemoglobin concentration below 110 g/L at sea level and categorized as mild (100–109 g/L), moderate (70–99 g/L), or severe (<70 g/L). True positive, true negative, false positive, and false negative rates were extracted for the reference and index tests in a 2×2 contingency table. The parameters required to assess accuracy were recalculated in cases for which the sensitivity, specificity, positive predictive values, and negative predictive values were presented.

Study quality was assessed independently by SS and ER using the QUADAS-2 tool [14]. Four domains were evaluated: patient selection, use of the index test, implementation of the reference standard, and timing of the index test(s) and reference standard (“flow and timing”). Risk of bias (low, high, or unclear) and concerns about applicability of the findings were assessed for these domains. A high-quality study was one that had consecutive or randomized patient selection, had specific inclusion and exclusion criteria, and used recognized index and reference (gold-standard) tests that were performed with an appropriate delay between them.

2.4 Data analysis
The data were analyzed using STATA version 12.1 (Stata, College Station, TX, USA). True positive, false positive, true negative, and false negative rates were obtained from the publication or, if necessary, calculated from the reported estimates. The data were plotted in the receiver operating characteristic (ROC) space. When a sufficient number of studies was available, the diagnostic accuracy parameters were
pooled using a bivariate random-effect hierarchical model [19]. If fewer than four studies reported accuracy of a given test, the sensitivity, specificity, and likelihood ratio were pooled using a univariate model [20]. The 95% confidence interval (CI) was calculated for all estimates to indicate precision of test accuracy. Assuming a pre-test probability of 42% for a hemoglobin concentration of less than 110g/L [2,21], post-test probabilities for a negative and positive test result were calculated using an online calculator [22]. A pretest probability of 8% and 1% was used for moderate and severe anemia, respectively [21].

3 RESULTS
The selection process for the 10 studies included in the present systematic review is outlined in Figure 1. As shown in Table 1, these studies included 4239 pregnant women from seven LIMICs: India (n=2), South Africa (n=2), Sri Lanka (n=2), Benin (n=1), Kenya (n=1), Malawi (n=1), and Pakistan (n=1). Six index tests were identified and compared with a laboratory reference test. Five studies reported data on clinical examination [25–27,29,30], four on HCS [25,28–30], and three on the copper sulfate test [23,24,31]. HemoCue [25], the Sahli method [31], and a non-invasive hemoglobin sensor (NBM 2000) [32] were each reported in one study. The studies were published between 1996 and 2016. The prevalence of anemia (hemoglobin <110 g/L [12]) across the 10 studies was 23%–77%.

Quality assessment indicated that five (50%) of the studies had low risk of bias and low concern regarding applicability across all domains (Table 2). One (10%) study had a high risk of bias regarding patient selection. Three (30%) studies had an unclear risk of bias because the recruitment process was not adequately described.
One (10%) study had an unclear risk of bias regarding flow and timing. All studies had low risk of bias for applicability.

Accuracy of the on-site tests is outlined in Table 3. Seven studies provided diagnostic accuracy data for mild anemia (hemoglobin <110 g/L) [25,27–32]. Sensitivity ranged from 97% (copper sulfate) to 34% (NBM 2000). By contrast, specificity ranged from 92% (NBM 2000) to 62% (clinical assessment). Three studies also provided diagnostic accuracy data for mild anemia defined as hemoglobin <100 g/L [23–25]. Copper sulfate had 96% sensitivity (95% CI 89%–100%) and 89% specificity (95% CI 72%–99%); HemoCue had 94% sensitivity (95% CI 90%–97%) and 79% specificity (95% CI 75%–83%); HCS had 82% sensitivity (95% CI 76%–86%) and 45% specificity (95% CI 41%–50%); and clinical assessment had 73% sensitivity (95% CI 70%–76%) and 80% specificity (95% CI 77%–84%).

A general overview of the ROC data is shown in Figure 2, whereas ROC data for clinical assessment and HCS are shown in Figures S1 and S2, respectively.

Table S1 shows the data for moderate anemia (hemoglobin <80 g/L). One study [25] provided diagnostic accuracy data for three tests: clinical assessment (644 women), HCS (641 women), and HemoCue (671 women). Another study [31] provided data for copper sulfate (100 women) and the Sahli method (100 women) with a cutoff hemoglobin level of less than 88 g/L. HemoCue had 97% sensitivity (95% CI 85%–99%) and 94% specificity (95% CI 92%–96%); the Sahli method had 83% sensitivity (95% CI 85%–98%) and 93% specificity (95% CI 85%–98%); HCS had 82% sensitivity (95% CI 61%–93%) and 76% specificity (95% CI 73%–79%); copper
sulfate had 75% sensitivity (95% CI 55%–89%) and 94% specificity (95% CI 86%–98%); and clinical assessment had 62% sensitivity (95% CI 44%–77%) and 76% specificity (95% CI 72%–78%).

Data for severe anemia are also presented in Table S1. One study [25] defined severe anemia as a hemoglobin level of less than 60 g/L and provided accuracy data for three tests: clinical assessment (644 women), HCS (641 women), and HemoCue (671 women). Another study [31] defined severe anemia as a hemoglobin level of less than 66 g/L and provided accuracy data for copper sulfate (100 women) and the Sahli method (100 women). HemoCue had 83% sensitivity (95% CI 44%–97%) and 99% specificity (95% CI 98%–100%); the Sahli method had 75% sensitivity (95% CI 35%–97%) and 93% specificity (95% CI 86%–98%); copper sulfate had 63% sensitivity (95% CI 24%–91%) and 93% specificity (95% CI 86%–98%); HCS had 50% sensitivity (95% CI 15%–85%) and 98% specificity (95% CI 97%–99%); and clinical assessment had 50% sensitivity (95% CI 15%–85%) and 75% specificity (95% CI 71%–78%).

4 DISCUSSION

The present review assessed the accuracy of on-site tests to detect anemia in pregnancy. Copper sulfate, the Sahli method, and HemoCue had the highest sensitivities (≥85%). Furthermore, each of these methods performed better than did clinical assessment alone. Strengths of the present review included use of a systematic protocol. The analysis included studies of predominantly high quality that covered a wide range of tests and enrolled women with a range of anemia severity, which allowed generalization across the spectrum of the disease.
Cyanmethemoglobin spectrophotometry is the global reference standard for detecting hemoglobin concentration [8]. A limitation of the present review was that it included studies that used any laboratory test as a reference standard, such as automated cell counters. Although these machines are calibrated against the reference standard, this calibration could have affected the accuracy of the test.

A univariate model was used to pool sensitivity and specificity estimates when fewer than four studies were available to compare the accuracy of the identified tests. Unlike a bivariate model, this approach did not account for the correlation between variables; however, estimates obtained using both models are reported to be similar [33]. Other limitations include the fact that only a small number of women had severe anemia; therefore, the accuracy of the data at this level might be unreliable.

Post-test probabilities for all evaluated tests were calculated assuming a 42% prevalence for anemia (hemoglobin <110g/L) [2]. After the test, among women who tested negative using the copper sulfate method, the prevalence of women who did not have anemia was reduced to 4%. Using the Sahli method or HemoCue, this probability was reduced to 11% and 12%, respectively. The HCS method performed poorly and only marginally better (reduction to 27%) than clinical examination alone (reduction to 29%). Reviews and studies have recommended the use of the HCS [11,30]; however, in the present review, this test had a high likelihood ratio for a negative test result, suggesting it might not be as clinically useful as previously reported. Additional training could increase its accuracy in a clinical setting because HCS performs well under laboratory conditions [34]. The non-invasive hemoglobin
probe NMB 2000 had low sensitivity but high specificity, which suggested that this test could be indicative of the presence of anemia in the context of screening.

In LIMICs, where resources are limited, many factors prevent the use of technologically advanced equipment, especially at a primary healthcare level [35]. Healthcare workers, therefore, need a simple, cheap, and robust device for measuring hemoglobin concentration [35]; nonetheless, this approach should not be at the expense of accuracy. Choosing the best test to use depends on factors such as cost, resources required, the setting in which it will be used, the skills of the healthcare workers, and ease of use. Therefore, the choice should probably be made at the local level. The HemoCue method is the most expensive test in terms of raw materials; however, the cost of training, procurement, and maintenance must also be considered. Taking the cost of the test in a resource-poor setting into account in combination with accuracy is also important.

A test should have high sensitivity if screening for anemia is used to decide which patients should be referred for further investigation and treatment. It is important not to miss women with severe anemia because this condition can have substantial clinical implications for both the mother and her offspring. Anemia has been linked with maternal mortality, increased risk of postpartum hemorrhage, sepsis, risk of intrauterine growth restriction, and preterm delivery [3,5]. The first step to reducing these risks would be identification of anemia so that the necessary treatment and monitoring can be initiated.
Increasing test sensitivity usually results in a concomitant reduction in specificity [36]. Using a test with high sensitivity but low specificity leads to unnecessary referrals for further investigation and so adds to costs for the health service [26]. However, clinical implications of test results also play a part. The consequence of missing a truly anemic pregnant woman has more severe clinical implications than does overtreatment. Most anemia cases that occur in pregnancy are secondary to iron deficiency; mild-to-moderate cases can be treated with iron tablets, which tend to be well tolerated [37]. For severe anemia, treatment-associated risk is increased because it might involve complex interventions such as blood transfusions. The adverse effects of these interventions can be serious (e.g. the spread of blood-borne disease) [38]. Testing is also important to monitor the effects of any intervention after the diagnosis is established, as well as for planning overall management of the affected woman, including place of delivery.

Additional research must be done on this topic: there were few studies available for inclusion in the present systematic review. It would also be interesting to evaluate novel non-invasive tests, especially those using readily available technology such as mobile phones [39]. Many studies have assessed devices for the detection of anemia; however, these investigations reported correlation coefficients that might be misleading and are less clinically useful than sensitivity and specificity. Reporting different measures can also limit the ability to perform meta-analysis. Future primary studies should be encouraged to report clinically useful accuracy variables. Furthermore, a detailed cost analysis of the accurate tests identified in the present study would be beneficial.
In conclusion, current reliance on clinical examination in LIMICs should be reduced, with the availability of accurate on-site tests increased, to help to improve the detection of anemia during pregnancy.

Author contributions
SS, ER and KSK conceived the research question, designed the protocol, and were involved in the literature search, study selection, and data extraction. ER performed the statistical analysis. SS and ER created the tables, figures, and appendices. SS ER, and KSK contributed to the both the draft and final versions of the manuscript.

Acknowledgments
The present study was supported by Ammalife (registered UK charity 1120236; funded SS), ELLY Appeal (funded SS), and WHO (funded ER). The listed charities had no influence on the development, conduct, or data reporting of the current systematic review.

Conflicts of interest
The authors have no conflicts of interest.

References


This article is protected by copyright. All rights reserved.
[10] Hiscock R KD, Simmons S: Systematic review and meta-analysis of method comparison studies of Masimo pulse co-oximeters (Radical-7™ or Pronto-7™) and HemoCue® absorption spectrometers (B-Hemoglobin or 201+) with laboratory haemoglobin estimation. *Anaesthesia and intensive care* 2015;43.(3): 341-350.


Figure legends

**Figure 1** Study selection process.
**Figure 2** Receiver operating characteristic curve of on-site test accuracy to detect mild anemia during pregnancy. Mild anemia was defined as a Hb level of either less than 110 g/L or less than 100 g/L. Abbreviations: Hb, hemoglobin; HCS, hemoglobin color scale.

Supporting information legends

**Appendix S1** Search history for the systematic review. The same search was used in all databases.

**Figure S1** Receiver operating characteristic curve of the accuracy of clinical signs to detect mild anemia (hemoglobin level <110 g/L) during pregnancy.

**Figure S2** Receiver operating characteristic curve of the accuracy of hemoglobin color scale to detect mild anemia (hemoglobin level <110 g/L) during pregnancy.

**Table S1** Accuracy of on-site tests used to diagnose anemia in pregnancy.
<table>
<thead>
<tr>
<th>Study</th>
<th>Country and setting</th>
<th>No. of pregnant women included</th>
<th>Index test</th>
<th>Reference test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pistorius et al. 1996 [23]</td>
<td>Pretoria, South Africa Public hospital</td>
<td>100</td>
<td>CuSO₄</td>
<td>Coulter counter</td>
</tr>
<tr>
<td>van den Broek et al. 1999 [25]</td>
<td>Malawi Three rural hospitals and two health centers</td>
<td>644</td>
<td>Clinical signs, HCS, and HemoCue</td>
<td>Coulter counter</td>
</tr>
<tr>
<td>Shulman et al. 2001 [26]</td>
<td>Mombasa, Kenya District hospital</td>
<td>1787</td>
<td>Clinical signs</td>
<td>Coulter counter</td>
</tr>
<tr>
<td>Fourn and Salami 2004 [27]</td>
<td>Benin Rural maternity clinic</td>
<td>480</td>
<td>Clinical signs</td>
<td>Spectrophotometry laboratory test</td>
</tr>
<tr>
<td>Prathapan et al. 2011 [28]</td>
<td>Colombo district, Sri Lanka Field prenatal clinics in 11 of 13 Ministry of Health areas in this district</td>
<td>101</td>
<td>HCS</td>
<td>Spectrophotometry Laboratory test</td>
</tr>
<tr>
<td>Chathurani et al. 2012 [29]</td>
<td>Anuradhapura district, Sri Lanka Ministry of Health field clinics in this district</td>
<td>115</td>
<td>Clinical signs and HCS</td>
<td>Cyanmethemoglobin method</td>
</tr>
<tr>
<td>Agnihotri et al. 2015 [31]</td>
<td>India Prenatal clinic in the Obstetrics and Gynecology department Jawaharlal Nehru Medical College</td>
<td>100</td>
<td>Sahli method and CuSO₄</td>
<td>Cyanmethemoglobin method</td>
</tr>
<tr>
<td>Ahankari et al. 2016 [32]</td>
<td>India Villages in Tuljapur and Lohara blocks of Osmanabad district, Maharashtra (n=33)</td>
<td>269</td>
<td>Non-invasive hemoglobin sensor (NBM 2000)</td>
<td>Sysmex analyzer XP-100</td>
</tr>
</tbody>
</table>

Abbreviations: CuSO₄, copper sulfate; HCS, hemoglobin color scale.
Table 2 Risk of bias of accuracy studies for tests to detect anemia during pregnancy.

<table>
<thead>
<tr>
<th>Study</th>
<th>Risk of bias</th>
<th>Applicability concerns</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patient selection</td>
<td>Index test</td>
</tr>
<tr>
<td>Pistorius et al. 1996 [23]</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>van den Broek et al. 1999 [25]</td>
<td>Unclear</td>
<td>Low</td>
</tr>
<tr>
<td>Shulman et al. 2001 [26]</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Fourn and Salami 2004 [27]</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Chathurani et al. 2012 [29]</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Prapathan et al. 2011 [28]</td>
<td>Low</td>
<td>High</td>
</tr>
<tr>
<td>Khan et al. 2015 [30]</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Agnihotri et al. 2015 [31]</td>
<td>Unclear</td>
<td>Low</td>
</tr>
</tbody>
</table>

* Risk of bias was measured using the QUADAS-2 quality assessment tool [14] and defined as low, high, or unclear.
### Table 3 Accuracy of on-site tests to diagnose mild anemia during pregnancy.a,b

<table>
<thead>
<tr>
<th>Index test</th>
<th>Prevalence, %</th>
<th>No. of studies</th>
<th>No. of women</th>
<th>Sensitivity, %</th>
<th>Specificity, %</th>
<th>Likelihood ratio (95% CI)</th>
<th>Post-test probability, %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Positive test result</td>
<td>Negative test result</td>
</tr>
<tr>
<td>Clinical</td>
<td>47 (27–72)</td>
<td>4</td>
<td>1853</td>
<td>56 (19–92)</td>
<td>62 (30–93)</td>
<td>1.7 (1.0–2.9)</td>
<td>0.57 (0.33–1.03)</td>
</tr>
<tr>
<td>HCS</td>
<td>42 (17–67)</td>
<td>4</td>
<td>1051</td>
<td>67 (56–76)</td>
<td>67 (48–82)</td>
<td>2.0 (1.3–3.1)</td>
<td>0.50 (0.40–0.62)</td>
</tr>
<tr>
<td>CuSO₄</td>
<td>58 (48–67)</td>
<td>1</td>
<td>100</td>
<td>97 (88–100)</td>
<td>71 (55–85)</td>
<td>3.4 (2.1–5.5)</td>
<td>0.05 (0.01–0.19)</td>
</tr>
<tr>
<td>Sahli method</td>
<td>58 (48–67)</td>
<td>1</td>
<td>100</td>
<td>86 (75–94)</td>
<td>83 (68–93)</td>
<td>5.2 (2.6–10.3)</td>
<td>0.17 (0.09–0.32)</td>
</tr>
<tr>
<td>Non-invasive hemoglobin sensor (NBM 2000)</td>
<td>77 (72–82)</td>
<td>1</td>
<td>269</td>
<td>34 (27–41)</td>
<td>92 (82–97)</td>
<td>4.1 (1.7–9.7)</td>
<td>0.72 (0.64–0.82)</td>
</tr>
<tr>
<td>HemoCue</td>
<td>23 (20–27)</td>
<td>1</td>
<td>671</td>
<td>85 (79–90)</td>
<td>80 (76–83)</td>
<td>4.3 (3.5–5.1)</td>
<td>0.18 (0.12–0.27)</td>
</tr>
</tbody>
</table>

Abbreviations: HCS, hemoglobin color scale; CuSO₄, copper sulfate.

a The pretest probability for mild anemia (hemoglobin <110 g/L) was 42%.
b Values in parentheses are 95% confidence intervals.
Identified studies (n=7779)
   Electronic databases (n=7766)
   References and other sources (n=13)

Full-text review (n=40)

Excluded (n=7739)
   Duplicates (n=1580)
   Exclusion criteria (n=6159)

Included in systematic review (n=10)
   Clinical assessment (n=4)
   Hemoglobin color scale (n=4)
   Copper sulfate (n=3)
   Sahli method (n=1)
   HemoCue (n=1)
   NBM 2000 (n=1)

Excluded (n=30)
   Conference abstracts (n=2)
   Technical performance reviews (n=4)
   Inappropriate populations (n=4)
   Prevalence studies (n=3)
   Inappropriate gold standards (n=6)
   Diagnostic accuracy data not included (n=11)

Duplicates (n=1580)

Exclusion criteria (n=6159)